ClinicalTrials.gg
TerminatedNCT06754761Updated Sep 3, 2026

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

A Phase 1 interventional study of [14C] AZD6738 and AZD6738 / ceralasertib in Neoplasm, sponsored by AstraZeneca. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Why this study was terminated
A decision, based solely on business strategy, was taken to terminate study D533BC00002 on 22 December 2025, as the clinical development programme for ceralasertib has been discontinued.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, two-part study in participants with solid tumours and will be conducted at multiple study sites.

Participants will be assessed for study eligibility prior to admission to the study site.

Participants may be enrolled in either Part A or Part B of the study or in both.

Part A will assess the absolute bioavailability, determine the excretory routes of [14C]-Ceralasertib, and evaluate the PK parameters of a Ceralasertib oral dose and a radiolabelled IV microdose of [14C]-Ceralasertib.

Participants will be admitted to the study site pre-dose Part A and will remain at the study site for excreta (urine and faeces) collections, PK sampling and safety assessments. A washout period days will be observed between dosing in Part A and Part B if participants are taking part in both parts of the study.

Part B will assess the ADME of [14C]-Ceralasertib.

Participants will be readmitted to the study site for Part B and will remain at the study site for excreta (urine, faeces, and any vomitus) collections, PK sampling, and safety assessments.

Participants will return to the study site for a Follow-up Visit after the last dose of Ceralasertib which will include routine safety assessments.

After the completion of Parts A and/or B, and following the Follow-up Visit, participants may be allowed further access to Ceralasertib if in the opinion of the investigator they may derive clinical benefit.

02

Conditions studied

  • Neoplasm

Browse trials for

Keywords

  • advanced solid tumours
  • hADME
  • bioavailability
  • AZD6738
  • ceralasertib
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 2 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:

Age

  1. Male or female ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the ICF.

    Type of Participant and Disease Characteristics

  2. Sufficient performance status, , and ability to swallow and retain oral medication
  3. Adequate organ and marrow function
  4. Willingness and ability to comply with study and follow-up procedures.
  5. Able and willing to stay in hospital for specified residential periods following administration of Ceralasertib/[14C]-Ceralasertib
  6. Regular bowel movements
  7. Locally advanced or solid tumour, for which standard therapy does not exist or has proven to be ineffective or intolerable.
  8. Sex and /Barrier Requirements: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  9. : patient must be capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:

    1. History of Diagnosis of protocol-specified medical conditions
    2. Spinal cord compression or prior to start of study intervention unless asymptomatic and stable
    3. Persistent toxicities ( Grade ≥ 2), with the exception of alopecia and vitiligo, caused by previous anticancer therapy.
    4. Any medical or surgical condition that would preclude adequate absorption of Ceralasertib
    5. Inadequate cardiac function / status or other cardiovascular diseases
    6. Participants with active infection requiring systemic antibiotics, antifungal or antiviral drugs
    7. Any evidence of severe or uncontrolled systemic disease, as judged by the investigator that would make it undesirable for the participant to participate in the study or would jeopardise compliance with the protocol
    8. Protocol-specified prior/concomitant therapy exclusions
    9. Protocol-specified prior/concurrent clinical study experience
    10. Other Exclusions including but not limited to tobacco/nicotine and/or alcohol use, or drug/alcohol abuse history
    11. Not currently pregnant, breast-feeding, or planning to become pregnant
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Primary Treatment Arm - AZD6738

    Part A - oral dose of Ceralasertib and a radiolabelled IV microdose of \[14C\]-Ceralasertib Part B - oral dose of \[14C\]-Ceralasertib

    Drug: [14C] AZD6738 · Drug: AZD6738 / ceralasertib

Interventions

  • radiolabeled AZD6738 / ceralasertib

  • DrugAZD6738 / ceralasertib

    Drug page: Ceralasertib

    Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR

06

What researchers measure

Primary outcomes

  1. To evaluate absolute bioavailability Ceralasertib and PK of Ceralasertib and [14C]-Ceralasertib after administration of oral dose of Ceralasertib and IV [14C]-Ceralasertib (Part A)

    Absolute bioavailability (F) of Ceralasertib and PK parameters and recovery in urine and faeces

    Time frame: Through end of Part A, approximately 5 weeks including screening period

  2. To determine the rates and major excretory routes of Ceralasertib and its metabolites after IV dose of [14C]-Ceralasertib (Part A) and a oral dose of [14C]-Ceralasertib (Part B)

    \[14C\]-Ceralasertib (Part A) or total radioactivity (Part B) recovery in urine and faeces

    Time frame: Through end of Part B, approximately 10 weeks including screening period

  3. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    AUCinf

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  4. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    AUClast

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  5. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    Cmax

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  6. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    tmax

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  7. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    t1/2(lambda)z

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  8. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    Ratio of AUCinf of plasma Ceralasertib relative to AUCinf of plasma total radioactivity

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  9. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B)

    Ratio of AUCinf of whole blood total radioactivity relative to AUCinf of plasma total radioactivity

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  10. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Urine Ae

    Urine - Ae

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  11. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Urine CumAe

    Urine - CumAe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  12. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Urine Fe

    Urine - Fe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  13. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Urine CumFe

    Urine - CumFe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  14. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Faeces Ae

    Faeces - Ae

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  15. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Faeces CumAe

    Faeces - CumAe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  16. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Faeces Fe

    Faeces - Fe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  17. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Faeces CumFe

    Faeces - CumFe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  18. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Total (Urine+Faeces) Ae

    Total (Urine + Faeces) Ae

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  19. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Total (Urine+Faeces) CumAe

    Total (Urine + Faeces) CumAe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  20. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Total (Urine+Faeces) Fe

    Total (Urine + Faeces) Fe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  21. To characterise the PK of Ceralasertib and total radioactivity following oral dose of [14C]-Ceralasertib including the extent of distribution into blood cells (Part B) - Total (Urine+Faeces) CumFe

    Total (Urine + Faeces) CumFe

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

Secondary outcomes

  1. To provide biologic samples for metabolic profiling and identification after oral dose of [14C]-Ceralasertib (Part B)

    Quantification and identification of major metabolites of Ceralasertib in plasma and excreta (will be reported separately)

    Time frame: Through end of the part B, approximately 10 weeks (Including screening period)

  2. To assess the safety of Ceralasertib in participants with advanced solid tumours (Parts A and B)

    Incidence and severity of AEs Incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results 12-lead ECG parameters Vital signs measurements Physical examinations

    Time frame: Through study completion, approximately 9 - 11 weeks, with screening included

07

Study locations

1 site
  • Research Site
    Liverpool, L7 8YA, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Oct 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Jan 1, 2025
StartActual
Sep 22, 2025
Primary completionActual
Oct 21, 2025
CompletionActual
Oct 21, 2025
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06754761
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Sep 22, 2025
Primary completion
Oct 21, 2025
Completion
Oct 21, 2025
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceralasertib

Start the discussion